LATEST ALERTS
Altria reported a solid performance in the first half of 2023 despite lower net revenues, partially offset by higher revenue in the oral tobacco segment
This report examines the main pathways for tobacco products to enter the market in the US, covering PMTAs, MRTPs and SEs
The US Food and Drug Administration (FDA) has posted a list of over 6m deemed new tobacco products for which it received Premarket Tobacco Product Applications (PMTAs) by the 9th September 2020 deadline
The US FDA’s granting of modified risk status to PMI’s IQOS system suggests possible future competition in the tobacco alternatives market, experts have told TobaccoIntelligence
Lawmakers in the US state of North Carolina are considering amending the rules on tax breaks for approved tobacco alternatives
This reports takes on a Q&A structure, providing a comprehensive overview of US regulations of oral nicotine products
Altria has submitted premarket tobacco product applications (PMTAs) to the US Food and Drug Administration (FDA) for 35 varieties of its On! nicotine pouches
The US Food and Drug Administration (FDA) has been granted a 120-day extension to the deadline for premarket tobacco product applications (PMTAs)
The US Food and Drug Administration (FDA) has requested a 120-day extension to the deadline for premarket tobacco product applications (PMTAs) due to the challenges that the coronavirus outbreak is posing to companies
The US Food and Drug Administration (FDA) has granted its first modified risk order for eight snus smokeless tobacco products to be sold with certain modified risk claims by Swedish Match USA
The US Food and Drug Administration (FDA) has grated its first ever modified risk orders to eight snus products from Swedish Match, which can now be advertised as less harmful than traditional cigarettes
PMI’s heated tobacco device IQOS and its associated consumables have been granted market authorisation by the FDA
There have been mixed reactions from within the industry to the FDA decision to allow PMI’s heated-tobacco device IQOS and its associated consumables onto the US market
The US FDA has given its approval for Philip Morris International (PMI)’s IQOS in the US, along with its associated consumables ― the first heated-tobacco products to be so approved
British American Tobacco (BAT) may get two heated-tobacco products onto the US market before IQOS can be launched there, thanks to its decision to take a different route to FDA approval
BAT has chosen to seek market authorisation in the US for its heat-not-burn product Glo on the basis of its “substantial equivalence” to a previous product, Eclipse – but what are the pitfalls and the advantages in this approach? …
The US FDA has missed its own 180-day deadline for replying to the premarket tobacco application (PMTA) by Philip Morris International for its IQOS heated tobacco products
The American Vaping Association has written to FDA commissioner Scott Gottlieb urging him to approve PMI’s heated tobacco product iQOS for sale in the US
As PMI’s iQOS comes under consideration by the US FDA, we examine the hurdles it – and other – heated tobacco and e-cigarette products will have to clear to obtain authorisation for commercialisation and reduced-risk claims.
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.
"*" indicates required fields
Get 7 days of FREE platform access: Demo our data contents without commitment
"*" indicates required fields
